Given the critical role of DNA repair in maintaining genomic stability, targeting these pathways has become a strategy in cancer therapy. PARP inhibitors are a class of drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP), which is involved in single-strand break repair. These inhibitors are particularly effective in cancers with BRCA mutations, as they exploit the concept of synthetic lethality.
